Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 144

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 144
---
% received from the 6th anniversary of the Closing date until the 10th
anniversary of the Closing date; (iii) 100% of the net proceeds received by the 10th anniversary of the Closing date for any license or disposition of the Company’s product candidates and/or intellectual property related to its RP-1664 program, RP-3500 (camonsertib) program, or any other license or disposition of the Company’s product candidates or research programs if such license or
disposition is entered into prior to the Closing date; (iv) 100% of the net proceeds received by the 10th anniversary of the Closing date for any license or disposition of the Company’s Polq
program, RP-3467, to any person with whom negotiations were initiated prior to the Closing date; (v) 50% of the net proceeds received by the 10
anniversary of the Closing date for any license or disposition of the Company’s product candidates and/or intellectual property that occurs within 10 years following the Closing date if such license or disposition is entered into following the
Closing date; and (vi) 100% of the net proceeds received by the 10 anniversary of the Closing date on account of certain investment tax credits, tax reimbursements or refunds, to the
extent attributable to the period (or portion thereof) prior to the Closing.

The right to the contingent payments contemplated by the CVR
Agreement is a contractual right only and will not be transferable, except in the limited circumstances specified in the CVR Agreement. The CVRs will not be evidenced by a certificate or any other instrument and will not be registered with the SEC.
The CVRs will not have any voting or dividend rights and will not represent any equity or ownership interest in Parent, any constituent corporation party to the Agreement or any of their respective affiliates. No interest will accrue on any amounts
payable on the CVRs to any CVR Holders.

87

AGREEMENTS INVOLVING COMMON SHARES

Voting and Support Agreements

On
November 14, 2025, each of the Company’s directors and officers, entered into a Voting and Support Agreement in connection with the Arrangement. Further, on November 20, 2025, certain shareholders of the Company, namely entities
affiliated with BVF Partners L.P., Blue Owl Healthcare Opportunities, and certain entities affiliated with OrbiMed, each entered into a support and voting agreement with the Company. The Voting and